Skip to main content
OpenTrials
Completed

NCT Number: NCT01937286

Single Center Experience Over a Decade in Living Donor Liver Transplantation for Egyptian Patients With Hepatocellular Carcinoma: Stretching the Limits

Within community with high incidence of HCC, stretching the limits could be justified based on tumor characters and its biological behavior

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–62 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Ain Shams Center For Organ Transplantation (ASCOT),Ain Shams university

Cairo, Egypt

About this study

590 Egyptian patients underwent LDLT; of them, 172 (32%) patients were transplanted for HCC. Twenty six cases (15.1%) were excluded due to early postoperative mortality (n=22) or due to non HCC related mortality (n=4). One hundred forty six patients were retrospectively reviewed to determine prognostic factors for recurrence.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Egyptien Patients with HCC
  • Patients within Milan Criteria
  • Patients beyond Milan criteria are selected on a case by case basis until 2005. From 2005 , patients beyond Milan criteria are subjected to down staging protocol and then reassessed (pre transplantation local ablative therapy either with RFA or TACE according to the size and the site of the lesion and we wait for 12 weeks after ablation ,only those with well ablated lesions, decreased AFP and no denovo lesions were transplanted).

Exclusion criteria

  • • Evidence of macro vascular invasion by CT portography and/or US duplex.
  • Metastatic HCC
  • General contraindications for LT (ongoing sepsis, other major co morbidities,…).
  • Early postoperative mortality (first1 month).
  • Post transplant mortality during the period of follow up due to any cause other than recurrent HCC (e.g. sepsis, rejection, cardiological or cerebrovascular complications…)

Treatment and study plan

Primary outcomes

  1. Recurrence of Hepatocellular carcinoma after LDLT

    Time frame: at least 6 months

Sponsors and collaborators

Lead sponsor

Ain Shams University

Other

Registry information

Important dates

Study start
2002
Primary completion
2011
Study completion
2012
First posted
Sep 9, 2013
Registry last updated
Sep 9, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.